6 530

Cited 0 times in

Efficacy and safety of solifenacin to treat overactive bladder symptoms in patients with idiopathic normal pressure hydrocephalus: an open-label, multicenter, prospective study

 Jae Hoon Chung  ;  Joo Yong Lee  ;  Dong Hyuk Kang  ;  U-Syn Ha  ;  Seung Hwan Lee  ;  Won Sik Ham  ;  Kang Su Cho  ;  June Hyun Han  ;  Jinsung Park  ;  Tag Keun Yoo  ;  Seung Wook Lee 
 NEUROUROLOGY AND URODYNAMICS, Vol.31(7) : 1175-1180, 2012 
Journal Title
Issue Date
Adult ; Female ; Humans ; Hydrocephalus, Normal Pressure/complications* ; Hydrocephalus, Normal Pressure/surgery ; Male ; Middle Aged ; Muscarinic Antagonists/adverse effects ; Muscarinic Antagonists/therapeutic use* ; Prospective Studies ; Quality of Life ; Quinuclidines/adverse effects ; Quinuclidines/therapeutic use* ; Severity of Illness Index ; Solifenacin Succinate ; Surveys and Questionnaires ; Tetrahydroisoquinolines/adverse effects ; Tetrahydroisoquinolines/therapeutic use* ; Time Factors ; Treatment Outcome ; Urinary Bladder/drug effects* ; Urinary Bladder/physiopathology ; Urinary Bladder, Overactive/diagnosis ; Urinary Bladder, Overactive/drug therapy* ; Urinary Bladder, Overactive/etiology ; Urinary Bladder, Overactive/physiopathology ; Urinary Bladder, Overactive/psychology ; Urodynamics ; Ventriculoperitoneal Shunt
clinical ; neurourology ; urodynamics
AIMS: To evaluate the efficacy and safety of solifenacin 5 mg to treat voiding symptoms caused by idiopathic normal pressure hydrocephalus (iNPH) after a ventriculoperitoneal (V-P) shunt operation.

METHODS: A total of 53 patients diagnosed with iNPH and complaining of voiding symptoms were enrolled. Before treatment with solifenacin (V1), 4 (V2) and 12 (V3) weeks after starting solifenacin overactive bladder symptom score (OABSS), the International Prostate Symptom Score (IPSS), Quality of Life (QoL) score, maximal urine flow rate (Q(max) ), voided volume, and post-voiding residual urine volume (PVR) were measured. An urodynamic study (UDS) was performed at V1 and V3, and the safety of solifenacin was assessed at V1, V2, and V3.

RESULTS: Of the 53 patients, 38 patients (71.70%) completed the 12-week clinical trial. The mean patient age was 52.24 ± 10.08 years. OABSS and IPSS were significantly improved. The mean voided volume was 147.18 ± 61.84 ml at V1 and 160.03 ± 62.59 ml at V3 (P < 0.001), and PVR was 64.87 ± 41.11 ml at V1 and 69.05 ± 39.54 ml at V3 (P = 0.009). Of the 31 patients who underwent UDS, 26 patients (83.87%) had detrusor overactivity (DO) at V1, with a mean value of 107.67 ± 18.13 ml. Of the 26 with DO at V1, 22 (84.62%) still had DO at V3. A mean DO of 131.66 ± 15.27 ml was observed at V3 (P < 0.001). The most common adverse effects was dry mouths.

CONCLUSIONS: Solifenacin is effective in the treatment of OABS in iNPH patients who underwent the V-P shunt operation. Solifenacin increases bladder capacity causing of DO at UDS.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Lee, Seung Hwan(이승환) ORCID logo https://orcid.org/0000-0001-7358-8544
Lee, Joo Yong(이주용) ORCID logo https://orcid.org/0000-0002-3470-1767
Cho, Kang Su(조강수) ORCID logo https://orcid.org/0000-0002-3500-8833
Ham, Won Sik(함원식) ORCID logo https://orcid.org/0000-0003-2246-8838
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.